Enrico Martin

178 Chapter 7 31. Byer SJ, Eckert JM, Brossier NM, et al. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. Neuro Oncol. 2011;13(1):28-41. doi:10.1093/ neuonc/noq146 32. Brosius SN, Turk AN, Byer SJ, et al. Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades. J Neuropathol Exp Neurol. 2014;73(11):1078-1090. doi:10.1097/NEN.0000000000000126 33. Albritton KH, Rankin C, Coffin CM, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol. 2006;24(18_suppl):9518. doi:10.1200/ jco.2006.24.18_suppl.9518 34. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27(19):3148-3153. doi:10.1200/JCO.2008.20.5054 35. Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133-3140. doi:10.1200/JCO.2008.20.4495 36. Schuetze SM, Wathen JK, Lucas DR, et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016;122(6):868-874. doi:10.1002/ cncr.29858 37. Johansson G, Mahller YY, Collins MH, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008;7(5):1237- 1245. doi:10.1158/1535-7163.MCT-07- 2335 38. Patwardhan PP, Surriga O, Beckman MJ, et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res. 2014;20(12):3146-3158. doi:10.1158/1078- 0432.CCR-13-2576 39. Castellsagué J, Gel B, Fernández-Rodríguez J, et al. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med. 2015;7(5):608- 627. doi:10.15252/emmm.201404430 40. De Raedt T, Walton Z, Yecies JL, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011;20(3):400 -413. doi:10.1016/j. ccr.2011.08.014 41. Malone CF, Fromm JA, Maertens O, DeRaedt T, Ingraham R, Cichowski K. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov. 2014;4(9):1062- 1073. doi:10.1158 /2159-8290.CD -14-0159 42. Watson AL, Anderson LK, Greeley AD, et al. Co-targeting the MAPK and PI3K/ AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget. 2014;5(6):1502- 1514. doi:10.18632/oncotarget.1609 43. Malone CF, Emerson C, Ingraham R, et al. mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov. 2017;7(12):1450-1463. doi:10.1158 /2159-8290.CD -17-0177 44. Yamashita AS, Baia GS, Ho JSY, et al. Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors. J Neurooncol. 2014;118(1):83-92. doi:10.1007/s11060- 014-1422-5 45. Dodd RD, Mito JK, Eward WC, et al. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther. 2013;12(9):1906-1917. doi:10.1158/1535- 7163.MCT-13-0189 46. Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123(1):340-347. doi:10.1172/ JCI60578